Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

"Declarations Ethics approval and consent to participateEthical approval to perform the study was sought from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and technology (Registration number: HS1032ES). Written consent was obtained before enrolment of study participants. Consent for publicationNot applicable. Competing interestsAll authors report no competing interests. Competing interests All authors report no competing interests."

"Funding NIH-Fogarty University of California (UCSF) global health fellowship program, grant number; 2D43TW009343-06, National Institutes of Health, UCSF-Gladstone Center for AIDS Research, Grant number; P30AI027763 and the Fogarty International Center of the National Institutes of Health, Infectious Diseases Institute –‘HIV and coinfections’ Award Number D43TW009771."

"Declarations: Ethics approval and consent to participateEthical approval to perform the study was sought from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and technology (Registration number: HS1032ES). Written consent was obtained before enrolment of study participants.: Consent for publicationNot applicable.: Competing interestsAll authors report no competing interests. Ethics approval and consent to participate: Ethical approval to perform the study was sought from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and technology (Registration number: HS1032ES). Written consent was obtained before enrolment of study participants."